Document Detail

Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year.
MedLine Citation:
PMID:  19466615     Owner:  NLM     Status:  MEDLINE    
The purpose of this study is to identify the factors that require arthroplasty due to the progression of joint destruction, even when an anti-tumor necrosis factor (TNF) biological agent is used for rheumatoid arthritis (RA). Among 91 cases that used the anti-TNF biological agent for more than 1 year, two groups of 21 cases that resulted in arthroplasty (surgery group) and 70 cases that did not result in arthroplasty (non-surgery group) were compared and examined. When the anti-TNF biological agent was first administered, disease activity and internal use of glucocorticoid (PSL) were not different in these two groups. The average DAS28-CRP(4) (disease activity score including a 28-joint count/C-reactive protein) (p < 0.001) and the amount of internal use of PSL (p < 0.05) were significantly decreased in the non-surgery group compared with the surgery group at the final survey. To inhibit the need for joint surgery in patients using the anti-TNF biological agent, it is important to maintain tight control over RA activity.
Hiroshige Sano; Katsumitsu Arai; Takehiro Murai; Junichi Fujisawa; Naoki Kondo; Takahiro Netsu; Tadamasa Hanyu; Takako Saeki; Tomoyuki Ito; Naoto Endo
Related Documents :
24842175 - Is video laryngoscope-assisted flexible tracheoscope intubation feasible for patients w...
23689115 - Structural and functional assessment of macula in patients with high-risk proliferative...
16385495 - The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radio...
24465035 - The effect of trapidil and bevacizumab on tracheal anastomotic wound healing.
6392105 - Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-c...
24579895 - Three- to six-year results of metacarpophalangeal joints arthroplasty in psoriatic arth...
Publication Detail:
Type:  Journal Article     Date:  2009-05-26
Journal Detail:
Title:  Modern rheumatology / the Japan Rheumatism Association     Volume:  19     ISSN:  1439-7595     ISO Abbreviation:  Mod Rheumatol     Publication Date:  2009  
Date Detail:
Created Date:  2009-08-04     Completed Date:  2009-11-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100959226     Medline TA:  Mod Rheumatol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  390-4     Citation Subset:  IM    
Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 1-754 Asahimachi, Chuoku, Niigata, Niigata 951-8520, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  pathology*,  physiopathology
Disease Progression
Drug Therapy, Combination
Immunoglobulin G / therapeutic use
Joints / drug effects,  pathology*,  physiopathology
Methotrexate / therapeutic use
Middle Aged
Prospective Studies
Receptors, Tumor Necrosis Factor / therapeutic use
Risk Factors
Severity of Illness Index
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Young Adult
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular characterization of hepatitis A virus isolated from acute gastroenteritis patients in the ...
Next Document:  Pituitary and systemic autoimmunity in a case of intrasellar germinoma.